Marksans Pharma Ltd. (MARKSANS) fundamentals
Marksans Pharma Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as MARKSANS (ISIN INE750C01026). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Marksans Pharma Ltd. does
Marksans Pharma Limited is an India-based company, which is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two research and development centers, one located in Goa and the other in Navi Mumbai. The Company's product portfolio spreads various therapeutic segments of the cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products (over-the-counter) include pain management, upper respiratory, digestive health, vitamins, minerals and supplements (VMS) and skin care products. Its prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic.
Valuation and market data
| Last close | ₹329.40 |
|---|---|
| Market capitalisation | ₹15,007 crore |
| Enterprise value | ₹14,654 crore |
| P/E (TTM) | 35.73 |
| Price to book | 4.92 |
| Price to sales (TTM) | 2.81 |
| Book value per share | ₹67.00 |
| Dividend yield | 27.32% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Jan 21 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,445 crore | ₹392 crore | ₹301 crore | 6.64 |
| Mar 2025 | ₹1,240 crore | ₹243 crore | ₹188 crore | 4.15 |
| Mar 2024 | ₹915 crore | ₹172 crore | ₹134 crore | 2.95 |
| Mar 2023 | ₹716 crore | ₹132 crore | ₹103 crore | 2.48 |
| Mar 2022 | ₹701 crore | ₹135 crore | ₹104 crore | 2.54 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 43.9% |
|---|---|
| Foreign institutions (FII) | 17.5% |
| Mutual funds | 4.4% |
| Other domestic institutions | 1.8% |
| Retail and others | 32.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.